Literature DB >> 8224241

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.

T Mattar1, K Kochhar, R Bartlett, E G Bremer, A Finnegan.   

Abstract

The active metabolite of leflunomide, A77 1726 inhibits the proliferation of a variety of mammalian cell lines in culture. Epidermal growth factor (EGF)-dependent proliferation is inhibited by A77 1726 at an effective dose of 30-40 microM. A77 1726 appears to directly inhibit the EGF receptor tyrosine-specific kinase activity both in intact cells and purified EGF receptors at the same effective dose. These data suggest that leflunomide inhibits cellular proliferation by the inhibition of tyrosine-specific kinase activities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224241     DOI: 10.1016/0014-5793(93)81704-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  29 in total

1.  A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.

Authors:  L C Hamilton; I Vojnovic; T D Warner
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).

Authors:  Sara A Colopy; Theresa A Baker; Peter Muir
Journal:  J Am Vet Med Assoc       Date:  2010-02-01       Impact factor: 1.936

3.  Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.

Authors:  K Thoss; S Henzgen; P K Petrow; D Katenkamp; R Brauer
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

Review 4.  Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

5.  Teriflunomide.

Authors:  Dennis J Cada; Kendra Demaris; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2013-03

Review 6.  Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  Ther Adv Neurol Disord       Date:  2014-09       Impact factor: 6.570

Review 7.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

Review 8.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Leflunomide inhibition of BK virus replication in renal tubular epithelial cells.

Authors:  Eva Bernhoff; Garth D Tylden; Lars J Kjerpeseth; Tore J Gutteberg; Hans H Hirsch; Christine H Rinaldo
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

10.  Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.

Authors:  K Migita; T Miyashita; H Ishibashi; Y Maeda; M Nakamura; H Yatsuhashi; H Ida; A Kawakami; T Aoyagi; Y Kawabe; K Eguchi
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.